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                      INTRODUCTION 
    Fibroadenoma (FA) is the most common tumour of breast in young 
females (<30 yrs) and second most common breast tumour in females. It 
is a benign condition. FA is responsible for 15% palpable breast lump. It 
is clinically presents as painless breast lump in reproductive age groups. 
FA is very rare as new lump over the age of 40 -45 yrs. 
      Most of the FA cases are self diagnosed and consult surgeon in fear of 
breast cancer. For the patients with small FA (<3cm) ,below the 30 yrs of 
age without suspicious cytology, FA is very slow growing hence simple 
observation with reassurance is enough because 15 to 30 % FA regress 
completely by simple observation over 1 to 6 yrs follow-up. 
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                     AIMS AND OBJECTIVES 
 The   purpose  of  this   study  is  to  find  the  REGRESSION OF 
FIBROADENOMA IN RESPONSE TO CENCHROMAN 
THERAPY (ORMELOXIFENE) in person who is willing for 
observation instead of excisional biopsy (enucleation) between 18 -30 yrs 
old. 
Study design: Randomized control trial 
Material: 80 Patients 
Study and follow-up period : 6 months 
INCLUSION CRITERIA: 
 
1. Diagnosed as FA under triple assesment 
          2.Age 18 to 30 year 
         3.Fibroadenoma of sonographic size 3 cm or <3 cm 
        4.Patient not willing for excision  (fear of scar) 
         5.Willing for observation with signed informed         
           Consent 
 
Exclusion criteria: 
     1. Patient above 30 yrs old 
 
2. Size larger than 3 cm 
 
3. Past history or family history of ca breast 
 
4. PCOD 
 
5.Liver disease, renal failure 
 
6. Lactation 
 
7.Pregnant and who desire to pregnant 8.Complex fibroadenoma 
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                                     HISTORICAL ASPECTS 
Galen 130-
200AD 
A greek physician mentioned about breast and 
used the word oncos for tumours. 
 6thcentuary Acoustics, the science of study started 
john moir   1620 Explained the breast is composed of small glands 
Jacques 
 
1880 piezoelectric effect discovered 
 1890 It was established that ovaries controls female 
reproductive system through a hormone. 
 
Sir Francis 
galton 
1893 constructed a whistle producing ultra      
     
  Sound 
 
Salomon 1913 noticed small block spots in xray film of 
amputated breast 
 
Paul langevin 1917 The first technological application of ultrasound  
was an  attempt to detect submarines 
 
  
Allen and Doisy 1923 doisy found alcoholic extract of 
ovaries was capable of producing 
estrus. 
 1929 active principle of estrogen obtained in 
pure form 
Dr. Ludwig 1940 Used ultrasonic energy as medical tool 
on the human body 
 
Leborgne 1951 Published his discovery that 
microcalcification are found in 30% of 
ca breast. 
EGAN et al 1980 Expressed “ the radiographic signs are 
so non specific that all punctuate 
microcalcification require histologic 
evaluation” 
Maimonides 
medical center 
1981 The first FNAC biopsy in the united 
sates was done and  
Eliminated the needs for 
hospitalization  for biopsy.  
LE Hughes 1987 Coined  ANDI first time. 
 1990 Centchroman (Ormeloxifene)marketed 
for OCPand DUB 
by Dhar A 
,Srivastava,aims, 
dpt of general 
surgery. 
2007 Role of centchroman in regression of 
mastalgia and fibroadenoma,Study 
done 
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           MATERIALS AND METHODS 
Patients attending general surgery op with complaints of breast lump 
between 18 to 30 yrs of age will be taken detailed clinical history, clinical 
examination,  ultrasonagram (USG) of  both breast and fine needle 
aspiration (FNAC)/ core needle biopsy 
               Patients who are all diagnosed as fibroadenoma (FA) and 
willing for simple observation with reassurance at least for 6 months will 
be included in this study after getting informed consent with sign in both 
tamil and English language. 
                    Willing patients after randomization included in study group 
and control group. Patients in study group will get Centchroman 30mg 
orally on alternative days and for control group patients only observation 
with simple assurance. Study group patients will be reviewed after 1 
week to check tolerance  and later follow-up at 4, 8, 12, and 24 weeks.  
USG will be done at 0 days, 12 and 24 weeks for both groups to  assess 
regression. 
        VOLUME OF FIBROADENOMA: 
        Size of FA was calculated by doing breast ultrasound using 7.5 –    
        MHZ linear probe on “Siemens versa” ultra sound scanner. Volume in  
        cubic centimetre is calculated by  using  following formula 
        SIZE – a × b × c × 0.52 
        a-largest dimension, 
        b- dimension at right angle to a.   
        c-a+b/2. 
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                REVIEW OF LITERATURE 
EPIDEMIOLOGY 
Benign breast diseases particularly  fibroadenoma  because of its high 
prevalence, fear of cancer and its impacts on quality of women life. It is the 
most common benign tumour of the breast below 30 yrs old females. It  comes 
under Aberration in normal development and involution (ANDI). Incidence of 
fibroadenoam is 15 % of all palpable breast lumps. FA is bilateral in 20 % and 
multiple in 20 % of cases. 
Fibroadenoma is common in blacks and negroes.Endocrine factors are involved 
in the etiology of fibroadenoma but their precise roles remains to be 
elucidated. There is no modifiable risk factor for fibroadenoma. Benign breast 
disorders has an incidence of 1.5/1000 
total hospital admissions, 6.4/1000 of surgical admissions and 8.1/1000 of adult 
female admissions in india. 
                                              EMBRYOLOGY 
The epithelial/ mesenchymal interactions will give rise to the glandular tissue of 
the breast, can be seen at first on 5th or 6th weeks when two ventral bands of  
ectoderm, the mammary ridges/milklines, extend from axilla to inguinal region. 
Invagination of thoracic bud occurs on 49th day and the remaining mammary 
lines involutes. 
 
       
Thoracic ectodermal ingrowths branches into 15 to 20 solid buds which 
becomes the lactiferous ducts and their associated lobes of alveoli. They are  
surrounded by somatopleuric mesenchyme which forms the connective tissue, 
vasculature and fat which is invaded by the nerves. Proliferation, elongation and 
branching the  alveoli are formed and the duct system becomes well defined. 
Nipple formation occurs on 56th day and primitive duct develops on 84th days 
with canalization occurring on 150th day. The  ducts become canalized during 
the last 2 months of gestational period. Small mammary pit developed  by the 
epidermis at the point of original development of the mammary gland into 
which the lactiferous tubules open. Mesenchymal  proliferation forms the nipple 
perinatally. 
CONGENITAL INVERSION OF NIPPLE 
        It occurs in 3% of female population. Bilateral in 85% cases and 
unilateral in 15% cases. It  may cause recurrent mastitis and difficulty 
in breast feeding and has psychological implications but it can be 
corrected surgically. 
         
ATHELIA -Congenital absence of nipple but this occurs commonly in 
accessory breast tissue 
Polymastia- supernumerary breast 
Polythelia- Supernumerary nipples which is more common in males. 
Amastia –Congenital absence of breast 
Amazia-nipple development without breast tissue 
                                   BREAST ANATOMY 
            Breast is a modified sweat gland which vertically extends from 2nd to 6th 
rib in the MCL and horizontally from the side of sternum to mid axillary line 
and lies over pectoralis major, serratus anterior and external oblique muscles. 
It forms secondary sexual character of females and it is the eource of nutrition 
for neonates. It also present males but in rudimentary form. Shape and size of 
the breast depends on the of the racial, genetic,dietary factors and the age, parity 
and menopausal status of the individual. 
                        
 
SKIN 
Female breast is covered by modified thin skin of the anterior thoracic wall and 
bears fine hairs. Skin over the nipple and areola lacks hair and contains sweat 
and sebaceous glands which open directly . Oily secretion from this sebaceous 
gland  form protective lubricant during lactation.  Melanocytes are numerous in 
nipple and areola complex 
   Skin of the breast supplied by branches from the 1.anterior intercostals 
arteries 2.lateral thoracic artery, a branch of axillary artery 3.posterior 
intercostals arteries. 
Venous drainage of nipple and areola forms circular venous plexus which drains 
into the veins accompanying corresponding arteries. 
                     Lymphatics from the lateral side of breast skin drains into pectoral 
nodes ,lymphatics from skin near drains into parasternal nodes  and there is 
anastamosis across the sternum and few from upper pectoral region drains into 
inferior deep cervical nodes. 
SOFT TISSUE 
         Breast is composed of 15-20 lobes each of which consist of branching 
ducts and terminal lobules in a stroma. Stroma around the lobules  is dense and 
fibrocollaagenous but intralobular connective tissue has a loose texture which 
enables rapid expansion during pregnanacy. Adipose tissue in the interlobar 
stroma is responsible for increase in breast size during pregnanacy. 
AXILLARY TAIL OF SPENCE: 
It is a prolongation of the outer part of the mammary gland and reach upto the 
level of the 3rd rib in axilla   through foramen of langer in the deep fascia which 
is in direct contact with the axillary lymphnodes. 
Retromammary bursa is located between the deep layer of superficial fascia and 
pectoral fascia. 
Suspensory ligament of cooper- It is a band of connective tissue which connects 
skin and deep fascia and anchor the breast. 
ARTERY 
       1.Axillary artery through thoraco acromial artery, lateral thoracic   
       artery and subscapular branches 
       2.Internal thoracic artery through perforating branches 
        3. 2nd to 4th intercostals arteries 
                     
 
 
 
VEINS 
         There is circular venous plexus around the areola. Blood from this circular 
venous plexus and gland drains via veins accompanying correspond arteries. 
LYMPHATIC DRAINAGE 
                There are 20 to 40 axillary nodes receive more than 75% of the lymph 
from the mammary gland which is grouped into pectoral, subscapular, central 
and apical groups and surgically these nodes described in relation to pectoralis 
minor. Lymphatic drainage from the the subareolar plexus of sapppey and outer 
quadrant of the breast takes place first to the pectoral, central and lostly to the 
apical nodes. The other two groups of axillary nodes viz the subscapular and 
lateral group may be involved in a retrograde manner. From the apical group 
supraclavicular group may be involved. The upper quadrant of the breast drains 
partly to deltopectoral nodes but  mainly to the apical group. From the inner 
quadrant of the breast the lymph spread occurs to the internal mammary group 
and to the other breast. From the lowe and inner quadrant of the breast the 
lymph vessels form a plexus over the rectus over the rectus sheath and pierce 
the costal margin to communicate with subperitoneal lymph plexus known as 
transcoelomic implantation . 
                     
Level 1-nodes lying below pectoralis minor 
Level 2-nodes behind the muscle 
Level 3-nodes between pectoralis minor and lower border of clavicle. 
Remainder drains into parasternal nodes. 
           
Microstructure: 
                 Depends on the  age, time of the menstruation period, pregnancy and 
lactation the microstructure of breast tissues varies. Almost entire length of the 
ducts are lined by columnar epithelium. In the larger ducts it is arranged  in two 
cells thick but smaller duct shows single layer of columnar or cuboidal cells. 
The bases of these cells in contact with numerous myoepithelial cells like other 
glandular epithelia. These numerous myoepithelial surrounds the ducts and  
alveoli and give the epithelium a bilayered appearance. 
                  Lactiferous ducts draining  each  lobe of the breast enters the nipple 
and open as 15 to 25 orifices. Near the opening, each of these ducts is slightly 
expanded as a lactiferous sinus which is further dilated in lactating mothers. 
                Each lactiferous duct is connected to a system of ducts and lobules 
which is surrounded by connective tissue stroma, ultimately forms the lobe of 
the mammary gland. 
             Lobules made up of  portions of the glands that has the secretory 
potential. Depending upon the hormonal status these structure are variable. In 
the mature resting mammary gland each lobules consists of a cluster of blind-
ended, branched ductules whose ends lack terminal alveoli, which are the 
source of  milk secretion in the lactating breast. 
 Keratinized stratified squamous epithelium replacing stratified cuboidal 
epithelium near the opening of lactiferous ducts in the nipple. 
                  Nipple is internally composed of collagenous dense connective 
tissue and contains numerous elastic fibres. Smooth muscle cells are  arranged 
in circular fashion are lie deep to the nipple. 
ABERRATIONS OF NORMAL DEVELOPMENT AND INVOLUTION 
(ANDI)   OF THE BREAST 
             It is described by the Cardiff  breast clinic. Pathogenesis involves 
disturbance in the normal breast physiology extending from slight deviation  of 
the  normality to  well defined disease process. 
                    It includes variety of benign breast disorders happening at different 
periods of the reproductive periods of  the females. Early, matured and 
involution stage of  reproductive  period. All disorders under ANDI should  be 
carefully examined clinically and often USG, mammography  and FNAC/core 
cut biopsy done to rule out malignant conditions. 
                It is based on three phases of normal physiology of breast. 
1.lobular development   2.cyclical hormonal modifications 3.Involutions. 
Pathology: This disease consists of four features essentially 
1. Cyst formation-it is almost inevitable and variable in size 
2.  2.fibrosi –elastic and fat tissues are replaced by dense white fibrous 
trabeculae. The interstitial tissue is infiltrated with chonic inflammatory 
cells 
3. 3.hyperplasia  -hyperplasia of the epithelium in the lining of the ducts and 
acini may occur with or without atypia 
    4.Papillomatosis-The epithelial hyperplasia may be so extensive that it results    
     in papillomatous overgrowth within the ducts. 
MANIFESTATION OF ANDI:  The commonest manifestation of ANDI are 
cyclical pain and nodularity.when when pain is a prominent symptom. This 
should be assessed apart from nodularity. Such pain is classified unto cyclical or 
premenstrual mastagia and non cyclical mastagia. Cyclical mastalgi is  
Related to ANDI and noncyclical mastalgia is not related to ANDI. It is usually 
due to musculoskeletal origin of the chest wall or it may be associated with 
inflammatory episodes caused by duct ectasia or periductal mastitis. Keep in 
mind that persistent , localized pain or discomfort  may be a symptom of cancer. 
 Nodularity or lump of the breast is the most common symptom. It may be 
associated with pain. Sometimes the pain  only draw the patient attention to 
lump in breast. These lumps usually located in the upper and outer quadrant of 
the breast and lumps in these areas are noticed easily than the lumps located in 
the centre and inner quadrant of the breast. These lumps become more larger 
and painful during premenstrually.  Eventhough  it is difficult for the patient to 
judge whether the swelling is gradually increase in size or not but if the patients 
tell that the lump fluctuate in size is particular to this condition and excludes 
carcinoma breast . lumps may be single or multiple and  may be sudden in 
onset. Lumps are often cyst and changes in secretory activity of breast leads 
give to rise of such cyst. Cyst may be single, multiple and vary in size. Cysts are 
usually smooth, round and variable in consistency . Fluctuation can be elicited if 
the cyst are located superficially and very tense cyst is not fluctuant and very 
hard.  Diffuse nodularity is often bilateral and found mainly in the upper and 
outer quadrant. If  the patient first came at menstrual period better to Reexamine 
the patient in first half of the menstrual period. 
Focal nodularity must be examined properly to rule out the carcinoma breast.    
EARLY REPRODUCTIVE AGE GROUP (15-25 YRS) 
        Normal lobule development may present as aberration as FA. If it is more 
than 5cm it is called giant fibroadenoma as a diseased status. 
       Normal stroma may develop juvenile hypertrophy as aberration and 
multiple fibroadenoma 
IN MATURE REPRODUCTIVE AGE GROUP (25 TO 40 YRS) 
 Exagerrated normal cyclical hormonal effect on stroma and on glands may 
present as aberration cause generalised enlargement of the mammary gland. Its 
diseased status is cyclical mastalgia with nodularity also known as 
fibrocystadenosis. 
INVOLUTION AGE GROUP (40-55 YRS) 
LOBULAR INVOLUTION with adenosis, microcyst, fibrosis, apocrine 
metaplasia and eventual aberrations as macrocyst and cystic disease of the 
breast. Macrocyst is an ANI.sclerosing adenosis is also a type of aberration. 
DUCTAL IVOLUTION may cause ductal dilatation and  nipple  discharge as 
aberration. Later disease status develops with bacterial infection, periductal 
mastitis, mammary duct fistula and non lactational brest abscess. Partial nipple 
retraction may be caused by periductal fibrosis. 
EPITHELIAL CHANGES leads into epithelial hyperplasia and atypia.  
  
 
                                     
 
                                     
   
FIBROADENOMA 
     Fibroadenoma  (FA) or adenofibroma is a benign tumor composed of fibrous 
tissue and epithelial elements. It is a common cause of discrete, firm, and 
mobile lump in  breast between 15 to 25 yrs old age group.  
It is considered asan aberrations  in ‘development and involution  of 
ductotubular tissue’ in the breast and not a true neoplasm.  
It begins as a hyperplasia of the lobules from the terminal ductal lobular units 
which progressively increase in size from 1 to 3 cm.                                                   
The main symptom of fibroadenoma is painless lump in the breast. FA is a slow 
growing tumour and remains more or less same size for a quite long time. It 
may occurs anywhere within the breast tissue but more oftenly seen in lower 
half of the breast than the upper half. 
On examination , the sweeling is not tender and without any temperature any 
rise in temperature. It is very smooth,firm and contains well defined border. 
This tumour is not fixed to skin or deeper structure. It is a highly mobile tumour 
without any tethering inside the breast substance. That is why it is often called a 
“ breast mouse” or “a floating tumor” . There   is no enlargement of axillar 
lymph nodes. Some Most of the lesions single , discrete and static but 
sometimes  multiple lesions can occur in the same breast or bilaterally.  
Near10 – 15 % lesions disappears spontaneously over a period of 6 to 60 
months on observation itself. 
Fibroadenoma is considered to arise from hyperresponsiveness of lobular tissue 
to estrogen. Presence of estrogen receptors on tissue obtained from 
fibroadenoma has been described.  
Hence antiestrogen ,Centchroman(Ormeloxifene)can be used to suppress the 
proliferation of ductolobular tissue of fibroadenoma. 
Sometimes soft fibroadenomas may  may undergoes cystic degeneration leading 
to cystadenoma which ultimately transform to cystosarcoma phylloides. 
Cystosarcoma phylloides (Serocystic disease of brodie): this is real giant 
fibroadenoma, seen in women over the age of 40 yrs. main complaint is large 
swelling , though occasionally may may present as nipple discharge from the 
nipple. It is not malignant condition. It doesn’t infiltrate the skin but the 
overlying skin becomes thin and tense and subcutaneous veins become 
prominent. This tumour is not fixed to  deeper structure. Sometimes axillary 
nodes become rarely enlarged  but mostly it is because of secondary infection. 
Grossly classified as 
1.soft-more cellular and often bilateral. Seen in more than 30 yrs old. 
2.hard –more fibrous , common below 30 yrs 
3.giant- size more than 5 cm. 
Microscopically classified as 
1.Intracanalicular  
It contains more glands which  becomes stretched into elongated spidery shapes 
and become indented by fibrous tissue. This type of fibroadenoma are soft and 
larger in size. Which occurs in middle aged females between 35 to 50 yrs. 
2.Pericanalicular 
Pericanalicular FA  which is made up of fibrous tissue surrounding  small 
tubular glands. This type of FA is small and hard. Which occurs in young 
females between 15 to 35 yrs old.  
          
Clinically presents as painless swelling in one of the breast quadrant which is 
smooth, nontender, firm, well localised and freely moves within the breast 
Juvenile fibroadenoma- seen in adolescent girls. It shows rapid growth with 
stromal and epithelia hyperplasia but doesn’t show alteration in the stromal 
epithelial balance/ cellular atypia/ periductal cellular concentration. Clinically it 
mimics phylloides but doesn’t turn to phylloides or carcinoma. 
Complex fibroadenoma- it is a typical FA with fibrocystic changes like cyst 
formation, apocrine metaplasia, sclerosing adenosis. It occurs in old age groups. 
Occasionally turn into malignancy. Core biopsy needed to confirm the 
condition. 
Investigations  
1.Mammography   2.FNAC  3.USG 
Indication for surgery 
1.size > 3 cm  2.multiple  3.giant type  4.recurrence  5.cosmesis         
 6. Complex type  7.family history of ca breast. 
Surgery: 
Enucleation is done  under general anaesthesia 
                           
 
Types of incision 
1.webster `s incision- circumareolar incision 
2. Gaillard Thomas incision-submammary incision. 
Conservative management of FA: 
Patient under 30 yrs old doesn’t require excision unless associated with 
suspicious cytology, or if it is >3cm size, or patient desires the lump to be 
removed. 
  For these patients regular follow-up with usg at 6monthly interval with  simple 
observation is enough. 
         
 
 
 FINE NEEDLE ASPIRATION CYTOLOGY (FNAC) 
It is the least invasive method to obtain a cell diagnosis which is rapid and 
accure if both cytologist and operator are experienced but false negative may 
occur. This procedure involves aspiring cells and attendant fluid with a small 
bore needle, followed by cytologic examination of the stained smear. This 
method is mostly useful for readily palpable lesions in sites such as thyroid, 
lymphnode and breast. Although it has some difficulties,  such as small sample 
size and sampling errors, in experienced hands it is extremely rapid, reliable and 
useful. Modern imaging techniques like usg permit extension of the method to 
lesions in deep seated structures like pelvic lymph node . 
It can be done with 22 gauge needle. With the lump held properly, the needle is 
passed multiple times into the lump  with negative pressure continuous 
aspiration till obtaining adequate material through the needle. Then needle 
witsyringe is removed without negative pressure. 
                                                                                                                    
        
The aspirate is properly prepared over the slide for cytological examination 
using 100% alcohol. Cytology is studied after staining it under microscopy. 
Usg guided fnac: useful when  the breast lump is not papable clinically, very 
deeply located and difficult to hold 
            
FNAC picture of fibroadenoma: 
  1.A high yield of cells, myxoid substance & some macroscopically  
  visible tissue fragment 
  2.Large , branching sheets of bland epithelial cells( staghorn pattern      
  of epithelial cells) 
  3.numerous single, bare bipolar nuclei 
  4.Fragments of fibromyxoid stroma. 
                             
                          
  
Large needle biopsy -Sampling error decreases as the as per biopsy 
volume increases and using 8G or 11G needles allows more tissue to 
be taken. 
                              ULTRASONOGRAM (USG) 
Ultrsound is inexpensive, quick, reliable and non invasive and it is the initial 
investigation of choice for wide range of clinical problems.usg is technically 
demanding and it  need experienced operator to maximise the diagnostic 
reliability. Inspite in the advancement in technology, there are still problem with 
gas because it reflects sound completely and in obese patients hence both are 
unsuitable for ultrasonagram. Ultrasound is based on the generation of high 
frequency sound waves, usually between 3 to 7 MHz. Recent range of 
ultrasound includes probes measuring only millimetres and operating at 20 
MHz. 
It is useful to identify whether the lump is cystic  or solid. Particularly useful in 
patients with dense breast. Usg is useful to localise impalpable areas of breast 
pathology. It is not useful as a screening tool. 
          FA appears oval on usg and their width is larger than anteroposterior 
diameter. Well circumscribed margins with gentle lobulations present . 
                                  
                    
                   
Internal echogenicity may be homogenous but finding may range from 
isoechoic to hypoechoic. The through transmission of the tumour is variable. 
Thin echogenic capsule is typical of FA which denotes the lesion is benign. This 
thin capsule is not true capsule ,it s a pseudocapsule which is formed by 
compression of adjacent structures 
By using color –flow Doppler or power doppler imaging the distribution and 
vascularity of FA is highly variable hence vascularity of breast solid masses 
doesn’t help to distinguish a cancer from FA. 
                                    
 
                                       
 
 
 
 
                                     ESTROGENS 
      It is a female sex hormones. Mainly synthesized from the ovaries. The most 
potent natural estrogen for both estrogen recptors  (ERα,ERβ) is 17β  estradiol 
followed by estrone and estriol. Each molecule contains a phenolic  A ring with 
a hydroxyl group at carbon 3 and a β-OH or ketone in position 17 of ring D. 
         The phenolic A ring is responsible for selective affinity for both receptors. 
Ethinyl substitutions at C17 position imcreases oral potency by blocking first 
passs metabolism in liver. 
NATURAL ESTROGEN  
Estradiol is the major estrogen synthesized from  the ovary. It is secreted from 
corpus luteum, graafian follicle  and placenta which is produced from 
cholesterol. 
 
Estradiol is 
immediately oxidized to estrone in the liver . Estrone is hydroxylated to estriol. 
All the three hormones which  mentioned above are found in the blood but 
among these estrdiol is the high potent estrogen hormone.  
              In postmenopausal women, the principle source of circulating estrogen 
is adipose tissue stroma, where estrone is synthesized  from 
dehydroepiandrosterone secreted by adrenals. 
REGULATION OF SECRETION: 
Menstruating women shows daily secretion of estrogen  10 to 100 µg depends 
on the phase of menstrual cycle. Graafian follicle  secretes estrogen under the 
influence of FSH and its blood level increases during the follicular phase. 
Because of preovulatory FSH surge , estrogen rises transiently further. After 
ovulation corpus luteum secrets estrogen till 2 days before to menstruation. 
                    Estrogen exhibits negative feedback action on FSH and also on LH 
at the higher concentrations in the blood. 
ACTIONS: 
1. Sex organs- It brings pubertal changes in the females including growth of 
vagina, fallopian tubes and uterus and it is responsible for proliferation 
endometrim in the preovulatory phase . 
    Even in the absence of progesterone withdrawal of estrogen itself can 
cause menstrual bleeding 
2. Secondary sexual characters- Estrogen produced after puberty leads to 
growth of breast by inducing proliferation of stroma , duct and  
accumulation of fat . it is also responsible for axillary and pubic hair 
growth and feminine body structures. 
3. Metabolic effects – it is a anabolic hormone and involved in maintaining 
bone mass primarily by inhibiting bone resorption. It supports positive 
calcium balance by inducing hydroxylase enzyme which involved in 
production of active form of vitamin D3. 
ESTROGEN RECEPTORS: 
The two estrogen recptors gene are located on separate 
chromosomes.ESR1 encodes ERα, and ESR2 encodes ERβ. Both 
estrogen receptors are estrogen-dependent nuclear transcription factors 
that have different tissue tissue tissue distributions and transcriptional 
regulatory effects on a wide number of target genes. 
Two types of estrogen receptors identified. 1.ERα 2.ERβ. Most of the 
tissues has both subtypes. ERα predominantly seen in breast, uterus, 
vagina, hypothalamus, and blood vessels. ERβ predominantly seen in 
ovaries in female and prostate in males. Estradiol binds with both 
receptors equally. 
MECHANISM OF ACTION 
              Estrogen bind to particular nuclear receptors and exhibits 
specific effect by regulating protein synthesize. ER are found  in female 
female sex organs, liver, pituitary,heart, cns, bones.   When it binds to the 
ligand binding domain  it leads to receptor dimerization and interaction 
with ERE of target genes. Gene transcription is promoted by certain 
coactivator proteins. When estrogen antagonist bind the receptor get a 
different conformation and interact with other  corepressor proteins 
inhibiting  gene transcriptions
 
THERAPEUTIC USES- The two major uses ofestrogens are for menopausal 
hormone therapy (MHT) and as components of combination  oral contraceptives 
Menopausal Hormone Therapy.-The   established   benefits of estrogen therapy 
in postmenopausal women include amelioration of vasomotor symptoms and 
the prevention of bone fractures and urogenital atrophy.  
 
 
SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM) 
It is a synthetic molecule. SERM can bind to both estrogen receptors and 
exhibits both estrogen agonist and antagonist action depends upon the target 
tissue. 
               
The pharmacological goal of these drugs is to produce beneficial estrogenic 
actions in certain tissues like bone , brain and liver during postmenopausal 
hormone therapy but antagonist activity in tissues such as breast and 
endometrium where  estrogen action might be deleterious.  Currently approved 
drugs in the USA are tamoxifen citrate, raloxifene hydrochloride and toremifene 
, which is chemically related and has similar actions to tamoxifene. Tamoxifene 
and toremifene are used for the treatment of breast cancer. Raloxifene is used 
primarily for the prevention and treatment of osteoporosis and to reduce the risk 
of invasive breast cancer in high risk postmenopausal women.  
ORMELOXIFENE ( CENTCHROMAN) 
It is a nonhormonal nonsteroidal antiestrogen (Selective estrogen receptor 
modulator, SERM) drug produced  by the Central Drug Research Institute, 
Lucknow, India. 
It has weak agonist action  on endometrium and strong antagonist action on 
breast ductolobular epithelium . Well absorbed from the GI tract. Peak serum 
levels attained in 4 hrs. widely distributed in body tissues  with little affinity to 
plasma proteins .Currently used as contraceptive and for DUB . centchroman 
has been available in india for birth control since 1990.It is marketed in the 
trade name as saheli, centron, sevista and novex.  
ADVERSE EFFECTS:  
Only significant adverse effect is menstrual abnormality.Others are nausea, 
headache, rise in BP, Weight gain. Menstrual periods will resume at the end of 
12 weeks. 
 
Contraindications  
1.Hypersensitivity to Ormeloxifene 
2.Renal impairment 
3.Hepatic impairment 
4.Jaundice 
5.Polycystic ovarian disease 
6.Chronic cervicitis 
7.Cervical hyperplasia 
8.Tuberculosis. 
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OBSERVATIONS AND RESULTS 
 
The collected data was analysed with SPSS 16.0 version.To describe about the 
data descriptive statistics frequency analysis, percentage analysis were used for 
categorical variables and the mean & S.D were used for continuous variables. 
To find the significant difference between the bivariate samples in Independent 
groups (Study group & Control group) Unpaired sample t-test was used. For the 
repeated measures (Volume zero day ,12th week & 24th week ) the Repeated 
measures of ANOVA with adjustment for multiple comparisons to control the 
type I error, the Bonferroni test was used.To find the significance in categorical 
data Chi-Square test was used. In all the above statistical tools the probability 
value .05 is considered as significant level. 
     P - 
Value Highly Significant at P ≤ .01 
 
    P - 
Value  Significant at P ≤ .05 
 
    P -
Value No Significant at P ≥ .05 
 
 
  
                  
Agerange * SC Crosstabulation 
  
SC 
Total 
STUDY 
GROUP 
CONTROL 
GROUP 
Agerange Upto 20 
yrs 
Count 19 19 38 
 % within 
SC 
47.5% 47.5% 47.5% 
21 - 25 yrs Count 12 14 26 
 % within 
SC 
30.0% 35.0% 32.5% 
26 - 30 yrs Count 9 7 16 
 % within 
SC 
22.5% 17.5% 20.0% 
Total Count 40 40 80 
% within 
SC 
100.0% 100.0% 100.0% 
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SC 
Total 
STUDY 
GROUP CONTROL GROUP 
 SIDE B Count 3 5 8 
% within 
SC 
7.5% 12.5% 10.0% 
L Count 17 18 35 
% within 
SC 
42.5% 45.0% 43.8% 
R Count 20 17 37 
% within 
SC 
50.0% 42.5% 46.3% 
Total Count 40 40 80 
% within 
SC 
100.0% 100.0% 100.0% 
  
Chi-Square Tests 
  Value df 
Asymp. 
Sig. (2-
sided) 
Pearson Chi-Square .772a 2 .680 
Likelihood Ratio .777 2 .678 
N of Valid Cases 80     
a. 2 cells (33.3%) have expected count less than 5. The 
minimum expected count is 4.00. 
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Crosstab 
 
  
SC 
Total 
STUDY 
GROUP 
CONTROL 
GROUP 
12WEEKS 
VOLUME CHANGE 
D Count 38 11 44 
% within 
SC 
95.0% 27.0% 61.3% 
I Count 2 16 23 
% within 
SC 
5.0% 40.0% 22.23% 
N Count 0 13 13 
% within 
SC 
0.0% 32.5% 16.3% 
Total Count 40 40 80 
% within 
SC 
100.0% 100.0% 100.0% 
Chi-Square Tests 
  Value df 
Asymp. 
Sig. (2-
sided) 
Pearson Chi-Square 28.194a 2 .000 
Likelihood Ratio 34.110 2 .000 
N of Valid Cases 80     
a. 0 cells (.0%) have expected count less than 5. The 
minimum expected count is 6.50. 
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D I N
 Crosstab 
  
SC 
Total 
STUDY 
GROUP 
CONTROL 
GROUP 
24WEEKS 
VOLUME CHANGE 
C Count 15 5 20 
% within 
SC 
37.5% 12.5% 25.0% 
D Count 22 6 37 
% within 
SC 
55.0% 15% 35% 
I Count 2 21 14 
% within 
SC 
5.0% 52.5% 28.5% 
N Count 1 8 9 
% within 
SC 
2.5% 20.0% 11.3% 
Total Count 40 40 80 
% within 
SC 
100.0% 100.0% 100.0% 
 
Chi-Square Tests 
  Value df 
Asymp. 
Sig. (2-
sided) 
Pearson Chi-Square 18.912a 3 .000 
Likelihood Ratio 20.687 3 .000 
N of Valid Cases 80     
a. 2 cells (25.0%) have expected count less than 5. The 
minimum expected count is 4.50 
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C D I N
  
MENSTRUAL ABNORMALITY * SC 
  
      Crosstab 
  
SC 
Total 
STUDY 
GROUP 
CONTROL 
GROUP 
MENSTRUAL 
ABNORMALITY 
Absent Count 32 37 69 
 % within 
SC 
80.0% 92.5% 86.3% 
Present Count 8 3 11 
 % within 
SC 
20.0% 7.5% 13.8% 
Total Count 40 40 80 
% within 
SC 
100.0% 100.0% 100.0% 
 
Chi-Square Tests 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-Square 2.635a 1 .105     
Continuity 
Correctionb 
1.686 1 .194     
Likelihood Ratio 2.721 1 .099     
Fisher's Exact Test       .193 .096 
Linear-by-Linear 
Association 
2.602 1 .107     
N of Valid Cases 80         
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 
5.50. 
b. Computed only for a 2x2 table 
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HEADACHE * SC 
      Crosstab 
  
SC 
Total 
STUDY 
GROUP 
CONTROL 
GROUP 
HEADACHE Absent Count 37 39 76 
% within 
SC 
92.5% 100.0% 96.2% 
Present Count 3 0 3 
% within 
SC 
7.5% 0.0% 3.8% 
Total Count 40 39 79 
% within 
SC 
100.0% 100.0% 100.0% 
       
Chi-Square Tests 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-Square 3.040a 1 .081     
Continuity 
Correctionb 
1.334 1 .248     
Likelihood Ratio 4.199 1 .040     
Fisher's Exact Test       .241 .125 
Linear-by-Linear 
Association 
3.002 1 .083     
N of Valid Cases 79         
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count 
is 1.48. 
b. Computed only for a 2x2 table 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
88%
90%
92%
94%
96%
98%
100%
STUDY GROUP CONTROL GROUP
HEADACHE
Absent Present
  
NAUSEA * 
SC 
     
      Crosstab 
  
SC 
Total 
STUDY 
GROUP 
CONTROL 
GROUP 
NAUSEA Absent Count 37 38 75 
% within 
SC 
92.5% 95.0% 93.8% 
Present Count 3 2 5 
% within 
SC 
7.5% 5.0% 6.3% 
Total Count 40 40 80 
% within 
SC 
100.0% 100.0% 100.0% 
Chi-Square Tests 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-Square .213a 1 .644     
Continuity 
Correctionb 
0.000 1 1.000     
Likelihood Ratio .215 1 .643     
Fisher's Exact Test       1.000 .500 
Linear-by-Linear 
Association 
.211 1 .646     
N of Valid Cases 80         
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count 
is 2.50. 
b. Computed only for a 2x2 table 
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SC = STUDY GROUP 
     
       Descriptive Statisticsa 
   
  Mean 
Std. 
Deviation N 
   DAY0VOLUME 8.718 3.6032 40 
   12 
WEEKSVOLUME 
2.560 3.1857 40 
   24 
WEEKSVOLUME 
1.865 3.9441 40 
   a. SC = STUDY GROUP 
   
       Mauchly's Test of Sphericitya,b 
    Measure: MEASURE_1 
    
  
Within 
Subjects 
Effect 
    
VOLUME 
    Mauchly's W .176 
    Approx. Chi-Square 65.968 
    df 2 
    Sig. .000 
    Epsilonc Greenhouse-
Geisser 
.548 
    Huynh-Feldt .552 
    Lower-bound .500 
    Tests the null hypothesis that the error 
covariance matrix of the orthonormalized 
transformed dependent variables is proportional 
to an identity matrix. 
    a. SC = STUDY GROUP 
    b. Design: Intercept  
 Within Subjects Design: VOLUME 
    c. May be used to adjust the degrees of freedom 
for the averaged tests of significance. Corrected 
tests are displayed in the Tests of Within-
Subjects Effects table. 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
       Tests of Within-Subjects Effectsa 
Measure: MEASURE_1 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
VOLUME Sphericity 
Assumed 
1138.061 2 569.031 79.737 .000 
Greenhouse-
Geisser 
1138.061 1.097 1037.785 79.737 .000 
Huynh-Feldt 1138.061 1.105 1030.368 79.737 .000 
Lower-bound 1138.061 1.000 1138.061 79.737 .000 
Error(VOLUME) Sphericity 
Assumed 
556.632 78 7.136     
Greenhouse-
Geisser 
556.632 42.768 13.015     
Huynh-Feldt 556.632 43.076 12.922     
Lower-bound 556.632 39.000 14.273     
a. SC = STUDY GROUP 
       Tests of Within-Subjects Contrastsa 
Measure: MEASURE_1 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
VOLUME Linear 939.135 1 939.135 81.909 .000 
Quadratic 198.926 1 198.926 70.868 .000 
Error(VOLUME) Linear 447.160 39 11.466     
Quadratic 109.472 39 2.807     
a. SC = STUDY GROUP 
       Pairwise Comparisonsa 
Measure: MEASURE_1 
(I) VOLUME 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.c 
95% Confidence 
Interval for 
Differencec 
Lower 
Bound 
Upper 
Bound 
1 2 6.157* .676 .000 4.466 7.849 
3 6.852* .757 .000 4.958 8.747 
2 1 -6.157* .676 .000 -7.849 -4.466 
3 .695* .200 .004 .195 1.195 
3 1 -6.852* .757 .000 -8.747 -4.958 
2 -.695* .200 .004 -1.195 -.195 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
a. SC = STUDY GROUP  c. Adjustment for multiple comparisons: Bonferroni. 
SC = CONTROL 
GROUP 
  
    Descriptive Statisticsa 
  Mean 
Std. 
Deviation N 
DAY0VOLUME 6.010 3.0856 40 
12 WEEKSVOLUME 4.990 3.7847 40 
24 WEEKSVOLUME 5.305 5.0035 40 
    
 
 
 
       
        
 
Tests of Within-Subjects Effectsa 
 Measure: MEASURE_1 
 
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. 
 VOLUME Sphericity 
Assumed 
21.822 2 10.911 2.603 .080 
 Greenhouse-
Geisser 
21.822 1.243 17.552 2.603 .106 
 Huynh-Feldt 21.822 1.264 17.262 2.603 .105 
 Lower-bound 21.822 1.000 21.822 2.603 .115 
 Error(VOLUME) Sphericity 
Assumed 
326.911 78 4.191     
 Greenhouse-
Geisser 
326.911 48.487 6.742     
 Huynh-Feldt 326.911 49.302 6.631     
 Lower-bound 326.911 39.000 8.382     
 a. SC = CONTROL GROUP 
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                      DISCUSSION 
   
 
Fibroadenoma is the  most common  tumour of females less than 30 yrs old and  
second most common neoplasm of females and 20 %  of the patient shows 
bilateral and 20 % shows multiple FA  After verifying lot of studies about the 
conservative management of mastalgia and benign breast  conditions like 
fibroadenoma and fibroadenosis , I decided to do this study  Instead of simple 
observation , if the patientt is willing since   15 %  of fibroadenoma will regress 
spontaneously   over 1 – 6 yrs observation. 
            According to the study “ regression of fibroadenoma with centchroman: 
a RCT” done by praksah laxmichand and tejwani et al,  was carried out in aims, 
department of general surgery , new delhi between nov 2004 to nov 2007 with 6 
months follow-up.  Study showed 31.88 % fibroadenomas in study group who 
had 30 mg centchroman od for 90 days  daily complete disappearance as 
compared to 7.69 % in control group.  
52.17% fibroadenomas decreased in size in study group as compared to control 
group. According to my study patients had centchroman 30 mg od on 
alternative days . 
  Among 80 patients 40 patients in study group and 40 patients in control group 
. 8 (10%) patients showed bilateral FA presentation.  
At the end of 12 weeks follow- up 38 (95%) patients showed decrease in size in 
study as compared to 11( 27%) in control group. 
At the end of 24 weeks follow-up  15 (37.5%) patients showed  complete 
disappearance compared to 5 (12.5%) patients in control group.  
22 (55%) patients showed decrease in size as compared to 6 (15%) patients in 
control group. 
 21(30%)  patients in control group showed increase in size compared to study 
group where 2 (5%) patients showed increase in size. 
8 (20%) patients showed menstruation abnormality compared to 3 (7.5%) 
patients in control group, it is satistically insignificant according my study. 
Only 3 (7.5)patients showed  headache in study group  as compared to o 
patients in control group. 
And 3 patients in study group complained nausea. 
As already explained Fibroadenoma is considered to arise due to 
hyperresponsiveness of lobular tissue to estrogen. Presence of estrogen 
receptors on tissue obtained from fibroadenoma has been described. Hence 
Centchroman(Ormeloxifene) has been used in this study .. 
But decrease in size of the FA even after 12th week  ( after centchroman 
regimen getting over) has been observed. It may be due to hit and run effect of 
the drug so it needs further study. 
 
LIMITATION OF THE STUDY: 
This study presents data based on 6 months follow-up only. Long term results of 
centchroman on recurrent and further decrease  in size require further studies in 
future. 
 
 
 
 
                          
                            
                                 
 
 
                                       
 
                            CONCLUSION 
 
 
                                                          
CONCLUSION: 
1.Centchroman therapy  in FA treatment showed satistifically significant 
regression of volume. 
2. Long term results beyond 6 months needs further study 
3. It is useful in patient who is willing for observation instead of  Enucleation of 
FA 
4. Patients more than 30 yrs old and  young patients  (<30 yrs)  with  suspicious 
histology, recurrence , family h/o carcinoma breast ,  anxiousness and no 
response to conservative management  are the ideal candidate  for active 
management  as excisional biopsy (enucleation of FA). 
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                               INFORMED CONSENT 
     GOVT. STANLEY MEDICAL COLLEGE, CHENNAI -600001 
DISSERTATION TOPIC: “REGRESSION OF FIBROADENOMA IN 
RESPONSE TO CENTCHROMAN THERAPY, A RANDOMIZED 
CONTROL STUDY”. 
PLACE OF STUDY: GOVT. STANLEY MEDICAL COLLEGE 
I,   ............................ have been informed about the details of the study in my 
own language. 
I have completely understood the details of the study. 
I am aware of the possible risk and benefits, while taking part in the study. 
I understand that I can withdraw from the study at any point of time and even, I 
will continue to receive the medical treatment as usual. 
I understand that I will not get any payment for taking part in the study. 
I will not object if the results of this study are getting published  in any medical 
journal, provided my personal identity is not revealed. 
I know what I am supposed to do by taking part in this study and I assure that I 
would extend my full co-operation for this study. 
 
 
Name and address of the volunteer: 
 
Signature/Thumb impression of the volunteer 
Date: 
Witnesses: 
(Signature , Name & Address) 
 
Name and signature of the investigator: 
DR SABARIMALI PALANISAMY 
 
  
 
 
                         
 
